Shionogi & Co. Ltd. and Pfizer Inc. have signed agreements with the National Health Service in England that will delink the payments they receive for their respective antibiotics Fetcroja (cefiderocol) and Zavicefta (ceftazidime–avibactam) from the volume of the drugs sold. The innovative subscription model that underlies the agreements is a world first and could provide a solution to stimulating more innovation in the field of developing new antibiotic and help tackle the problem of antimicrobial resistance (AMR).
England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.
More from Europe
More from Geography
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.